These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 13047681)

  • 41. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma.
    Jordan WP; Blackard CE; Byar DP
    South Med J; 1977 Dec; 70(12):1411-3. PubMed ID: 594790
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparative follow-up study of the therapeutic value of bilateral orchiectomy in the treatment of carcinoma of the prostate gland.
    SCOTT WW; BENJAMIN JA
    J Urol; 1948 Oct; 60(4):604-11. PubMed ID: 18885948
    [No Abstract]   [Full Text] [Related]  

  • 43. Treatment of carcinoma. Hormonal treatment and orchiectomy.
    Barnes RW
    Postgrad Med; 1969 Jun; 45(6):171 passim. PubMed ID: 5789387
    [No Abstract]   [Full Text] [Related]  

  • 44. [Treatment of cancer of the prostate gland by castration and sex rutting bodies].
    TRACZYK Z
    Pol Tyg Lek (Wars); 1948; 3(13):394-7. PubMed ID: 18881718
    [No Abstract]   [Full Text] [Related]  

  • 45. [Treatment of cancer of the prostate gland by castration and sex rutting bodies].
    TRACZYK Z
    Pol Tyg Lek (Wars); 1948; 3(14):430-2. PubMed ID: 18883543
    [No Abstract]   [Full Text] [Related]  

  • 46. CIRCADIAN VARIATION OF SERUM ACID PHOSPHATASE IN PROSTATIC CANCER.
    DOE RP; MELLINGER GT
    Metabolism; 1964 May; 13():445-52. PubMed ID: 14169223
    [No Abstract]   [Full Text] [Related]  

  • 47. THE MENOPAUSE: A PHYSIOLOGICAL CASTRATION.
    NAHUM LH
    Conn Med; 1965 May; 29():320-3. PubMed ID: 14327587
    [No Abstract]   [Full Text] [Related]  

  • 48. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hormonal therapy for stage D cancer of the prostate.
    Gudziak MR; Smith AY
    West J Med; 1994 Apr; 160(4):351-9. PubMed ID: 8023485
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hormonal treatment of prostate cancer.
    Smith S
    Ir Med J; 1996; 89(2):50. PubMed ID: 8682625
    [No Abstract]   [Full Text] [Related]  

  • 51. [Hormone therapy for prostate cancer].
    Théodore C
    Bull Cancer; 2004 Jan; 91(1):69-74. PubMed ID: 14975807
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Steroid hormone metabolites before and after orchiectomy for prostatic cancer.
    GALLAGHER TF; WHITMORE WF; ZUMOFF B; HELLMAN L
    J Clin Endocrinol Metab; 1963 Jun; 23():523-32. PubMed ID: 13960361
    [No Abstract]   [Full Text] [Related]  

  • 53. Tamoxifen in refractory metastatic carcinoma of the prostate.
    Glick JH; Wein A; Padavic K; Negendank W; Harris D; Brodovsky H
    Cancer Treat Rep; 1980; 64(6-7):813-8. PubMed ID: 7427966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LINEAR ACCELERATOR SUPERVOLTAGE RADIOTHERAPY. VII. CARCINOMA OF THE PROSTATE.
    BAGSHAW MA; KAPLAN HS; SAGERMAN RH
    Radiology; 1965 Jul; 85():121-9. PubMed ID: 14303057
    [No Abstract]   [Full Text] [Related]  

  • 55. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
    Moorjani S; Dupont A; Labrie F; Lupien PJ; Gagné C; Brun D; Giguère M; Bélanger A; Cusan L
    J Clin Endocrinol Metab; 1988 Feb; 66(2):314-22. PubMed ID: 3276721
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Hormonal treatment in cancer of the prostate].
    Boccon-Gibod L
    Rev Prat; 1987 Feb; 37(7):386-90. PubMed ID: 3823774
    [No Abstract]   [Full Text] [Related]  

  • 57. Endocrine therapy for prostate cancer.
    Sagalowsky AI
    Spec Top Endocrinol Metab; 1985; 7():101-29. PubMed ID: 3914094
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.
    Brogden RN; Faulds D
    Drugs Aging; 1995 Apr; 6(4):324-43. PubMed ID: 7613021
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prostate cancer--treatment of disseminated disease.
    Abi-Aad AS; Opsomer RJ
    Acta Urol Belg; 1996 May; 64(2):67-76. PubMed ID: 8701817
    [No Abstract]   [Full Text] [Related]  

  • 60. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective.
    Ahmed M; Li LC
    Int J Urol; 2013 Apr; 20(4):362-71. PubMed ID: 23163774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.